AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16638321 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 pneumoperitoneum
Number of subjects: 40
Study 16638321 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 40
Study 12936920 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meal + 0.5 g alcohol/kg body wt (M+A)
Number of subjects: 14
Study 12936920 — intervention group
Group type: COMPARATOR
Intervention: Test meal (M)
Number of subjects: 14
Study 10762288 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose GH therapy (1 U (0.5 mg) subcutaneously per day, n = 5)
Number of subjects: 16
Study 10762288 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose GH therapy (2 U daily, n = 5)
Number of subjects: 16
Study 10762288 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 16
Study 10762288 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy after placebo (n = 5)
Number of subjects: 16
Study 10762288 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued GH replacement (n = 9)
Number of subjects: 16
Study 8817982 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal pump (Lifestream; St. Jude Medical)
Number of subjects: 29
Study 8817982 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal pump (BP‐80; Medtronic)
Number of subjects: 29
Study 8817982 — intervention group
Group type: COMPARATOR
Intervention: Roller pump (Mera Co.)
Number of subjects: 29
Study 1597852 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular coffee
Number of subjects: 15
Study 1597852 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified caffeine (200 mg)
Number of subjects: 15
Study 1597852 — intervention group
Group type: COMPARATOR
Intervention: Placebo (highly decaffeinated coffee for regular coffee and china bitter extract for caffeine)
Number of subjects: 15
Study 1597852 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular coffee in habitual coffee drinkers (5 cups/day)
Number of subjects: 15
Study 4012507 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycoplasma pneumoniae
Number of subjects: 39
Study 4012507 — intervention group
Group type: COMPARATOR
Intervention: Matched comparative group
Number of subjects: 39
Study 31206607 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg rabbit anti-thymocyte globulin (ATG) for 5 days
Number of subjects: 222
Study 31206607 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 mg/kg rabbit anti-thymocyte globulin (ATG) for 5 days
Number of subjects: 222
Study 30308402 — intervention group
Group type: EXPERIMENTAL
Intervention: Marsupialization
Number of subjects: 134
Study 30308402 — intervention group
Group type: COMPARATOR
Intervention: Gland Excision
Number of subjects: 134
Study 26843138 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated Dietitian (DD) protocol
Number of subjects: 394
Study 26843138 — intervention group
Group type: COMPARATOR
Intervention: Control protocol
Number of subjects: 394
Study 26843138 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained Hospital Dietitian (THD) protocol
Number of subjects: 394
Study 1375678 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 316
Study 1375678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316
Study 22868187 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine
Number of subjects: 0
Study 20523078 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral risperidone orodispersible tablet
Number of subjects: 124
Study 20523078 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular haloperidol
Number of subjects: 124
Study 18670740 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (150-300 mg)
Number of subjects: 38
Study 18670740 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (20-40 mg)
Number of subjects: 38
Study 18670740 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 38
Study 16440578 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol cream applied once daily
Number of subjects: 13
Study 16440578 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol cream applied twice daily
Number of subjects: 13
Study 12790211 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Group (nitrous oxide 67% and oxygen 33% for 6 h)
Number of subjects: 16
Study 12790211 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuous Group (nitrous oxide for 3 h, then oxygen)
Number of subjects: 16
Study 12790211 — intervention group
Group type: COMPARATOR
Intervention: Control Group (nitrous oxide 67% and oxygen 33% for 6 h)
Number of subjects: 16
Study 10535248 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV (+) patients with SD
Number of subjects: 129
Study 10535248 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV (‐) patients with SD
Number of subjects: 129
Study 10535248 — intervention group
Group type: COMPARATOR
Intervention: HIV (+) patients without SD
Number of subjects: 129
Study 10535248 — intervention group
Group type: COMPARATOR
Intervention: HIV (‐) patients without SD
Number of subjects: 129
Study 8889909 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100-150 mg/day)
Number of subjects: 100
Study 8889909 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20-80 mg/day)
Number of subjects: 100
Study 1380148 — intervention group
Group type: EXPERIMENTAL
Intervention: CODE chemotherapy with recombinant human granulocyte colony-stimulating factor
Number of subjects: 0
Study 1380148 — intervention group
Group type: COMPARATOR
Intervention: CODE chemotherapy without recombinant human granulocyte colony-stimulating factor
Number of subjects: 0
Study 3880597 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.22‐micron IVEX‐HP filters
Number of subjects: 541
Study 3880597 — intervention group
Group type: COMPARATOR
Intervention: No filters
Number of subjects: 541
Study 31200465 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning (IPC) consisting of four cycles of five minutes followed by five minutes of reperfusion before IRI.
Number of subjects: 19
Study 31200465 — intervention group
Group type: COMPARATOR
Intervention: Ischemia-Reperfusion Injury (IRI) consisting of twenty minutes followed by 15 minutes of reperfusion.
Number of subjects: 19
Study 29505471 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK561679 (CRHR1 antagonist)
Number of subjects: 0
Study 29505471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27178257 — intervention group
Group type: EXPERIMENTAL
Intervention: DAGR 1 mg QD
Number of subjects: 323
Study 27178257 — intervention group
Group type: EXPERIMENTAL
Intervention: DAGR 5 mg QD
Number of subjects: 323
Study 27178257 — intervention group
Group type: EXPERIMENTAL
Intervention: DAGR 10 mg QD
Number of subjects: 323
Study 27178257 — intervention group
Group type: EXPERIMENTAL
Intervention: DAGR 15 mg QD
Number of subjects: 323
Study 27178257 — intervention group
Group type: EXPERIMENTAL
Intervention: DAGR 9 mg QD
Number of subjects: 323
Study 27178257 — intervention group
Group type: COMPARATOR
Intervention: Prednisone 5 mg QD
Number of subjects: 323
Study 27178257 — intervention group
Group type: COMPARATOR
Intervention: Prednisone 10 mg QD
Number of subjects: 323
Study 27178257 — intervention group
Group type: COMPARATOR
Intervention: Placebo QD
Number of subjects: 323
Study 25293764 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt containing 10(10) CFU Lactobacillus rhamnosus GR‐1 per 250 g
Number of subjects: 104
Study 25293764 — intervention group
Group type: COMPARATOR
Intervention: Whole milk or no intervention (control)
Number of subjects: 104
Study 19692197 — intervention group
Group type: EXPERIMENTAL
Intervention: High information provision
Number of subjects: 320
Study 19692197 — intervention group
Group type: COMPARATOR
Intervention: Low information provision
Number of subjects: 320
Study 16385833 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose internal brachytherapy (12 Gy)
Number of subjects: 209
Study 16385833 — intervention group
Group type: COMPARATOR
Intervention: Placement of an Ultraflex stent
Number of subjects: 209
Study 11979156 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg gadobenate dimeglumine
Number of subjects: 16
Study 11979156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9279536 — intervention group
Group type: EXPERIMENTAL
Intervention: acute hyperglycaemic hyperinsulinaemia (HG) with plasma glucose at 15 mmolL‐1
Number of subjects: 6
Study 9279536 — intervention group
Group type: EXPERIMENTAL
Intervention: euglycaemic hyperinsulinaemia (HI) with plasma insulin at 80 mUL‐1 and glucose at 4‐5 mmolL‐1
Number of subjects: 6
Study 9279536 — intervention group
Group type: COMPARATOR
Intervention: i.v. saline (control)
Number of subjects: 6
Study 9279536 — intervention group
Group type: EXPERIMENTAL
Intervention: acute hyperglycaemic hyperinsulinaemia (HG)
Number of subjects: 6
Study 9279536 — intervention group
Group type: EXPERIMENTAL
Intervention: euglycaemic hyperinsulinaemia (HI)
Number of subjects: 6
Study 8166529 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency jet ventilation (HFJV)
Number of subjects: 9
Study 8166529 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 9
Study 3209280 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 200 mg
Number of subjects: 12
Study 3209280 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg
Number of subjects: 12
Study 3209280 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg plus Ibopamine 200 mg
Number of subjects: 12
Study 11556763 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 1% cream, applied once daily for 7 days
Number of subjects: 0
Study 11556763 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study 11556763 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 1% cream
Number of subjects: 0
Study 31374668 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenge Point Framework (CPF) scheduling
Number of subjects: 23
Study 31374668 — intervention group
Group type: COMPARATOR
Intervention: Fixed scheduling
Number of subjects: 23
Study 29550384 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning (120 mg/m2 fludarabine + 4 doses of 2 Gy total-body irradiation)
Number of subjects: 195
Study 29550384 — intervention group
Group type: COMPARATOR
Intervention: Myeloablative conditioning (6 doses of 2 Gy total-body irradiation + 120 mg/kg cyclophosphamide)
Number of subjects: 195
Study 29550384 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning
Number of subjects: 195
Study 29550384 — intervention group
Group type: COMPARATOR
Intervention: Myeloablative conditioning
Number of subjects: 195
Study 26252868 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning methods applied to analyze conversations of suicidal adolescents
Number of subjects: 60
Study 26252868 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (nonsuicidal adolescents)
Number of subjects: 60
Study 25154982 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 7.5 mg/kg or 15 mg/kg plus chemotherapy
Number of subjects: 303
Study 22702147 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 72
Study 22702147 — intervention group
Group type: COMPARATOR
Intervention: Propofol anesthesia
Number of subjects: 72
Study 20818474 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAAs supplementation (0.4 g/kg/day and 0.2 g/kg/day)
Number of subjects: 30
Study 20818474 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 17362472 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 160/4.5 microg one inhalation bid plus additional inhalations as needed
Number of subjects: 3335
Study 17362472 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol/fluticasone 25/125 microg two inhalations bid plus as-needed terbutaline
Number of subjects: 3335
Study 17362472 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose budesonide/formoterol 320/9 microg one inhalation bid plus as-needed terbutaline
Number of subjects: 3335
Study 17362472 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol for maintenance and relief
Number of subjects: 3335
Study 17362472 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 3335
Study 15102873 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous palonosetron (0.3 to 90 microg/kg)
Number of subjects: 112
Study 15102873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 15102873 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous palonosetron
Number of subjects: 112
Study 11581434 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video intervention (20-minute video and brochure about antibiotics)
Number of subjects: 193
Study 11581434 — intervention group
Group type: COMPARATOR
Intervention: Control group (no video intervention)
Number of subjects: 193
Study 11581434 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video intervention (20-minute video)
Number of subjects: 193
Study 9704672 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug combination of docetaxel (75 mg/m2), ifosfamide (3,000 mg/m2), and cisplatin (75 mg/m2) with lenograstim support
Number of subjects: 12
Study 9704672 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug combination of docetaxel, ifosfamide, and cisplatin
Number of subjects: 12
Study 7991433 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation with iron sulfate 5 mg/kg until day 56
Number of subjects: 17
Study 7991433 — intervention group
Group type: COMPARATOR
Intervention: Control group (no iron supplementation)
Number of subjects: 17
Study 2567483 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (320 mg.d‐1)
Number of subjects: 74
Study 2567483 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg.d‐1)
Number of subjects: 74
Study 2567483 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg.d‐1)
Number of subjects: 74
Study 2567483 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 74
Study 5124439 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrantel embonate 100 mg/kg
Number of subjects: 60
Study 5124439 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrantel embonate 75 mg/kg
Number of subjects: 60
Study 5124439 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrantel embonate 50 mg/kg
Number of subjects: 60
Study 5124439 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrantel embonate 20 mg/kg
Number of subjects: 60
Study 5124439 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrantel embonate 15 mg/kg
Number of subjects: 60
Study 5124439 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrantel embonate 10 mg/kg
Number of subjects: 60
Study 30701726 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperspectral imaging (HSI)
Number of subjects: 32
Study 28627029 — intervention group
Group type: EXPERIMENTAL
Intervention: Test cream (moisturizer containing urea, glycerine, and petrolatum)
Number of subjects: 167
Study 28627029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 26742399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Thoracic Paravertebral Block (TPVB)
Number of subjects: 12
Study 26742399 — intervention group
Group type: COMPARATOR
Intervention: Epidural Analgesia
Number of subjects: 12
Study 23792400 — intervention group
Group type: EXPERIMENTAL
Intervention: Four bar-connected implants
Number of subjects: 49
Study 23792400 — intervention group
Group type: COMPARATOR
Intervention: Six bar-connected implants
Number of subjects: 49
Study 22013797 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduning Injection (RI)
Number of subjects: 76
Study 22013797 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Reduning Injection with Ribavirin Injection or antibiotics
Number of subjects: 76
Study 22013797 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (WM)
Number of subjects: 76
Study 18440201 — intervention group
Group type: EXPERIMENTAL
Intervention: dobutamine (5‐40 mug/kg/min)
Number of subjects: 30
Study 18440201 — intervention group
Group type: EXPERIMENTAL
Intervention: levosimendan (24 mug/kg in 10 minutes)
Number of subjects: 30
Study 16945029 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with dentifrice
Number of subjects: 120
Study 16945029 — intervention group
Group type: COMPARATOR
Intervention: Brushing without dentifrice
Number of subjects: 120
Study 16945029 — intervention group
Group type: EXPERIMENTAL
Intervention: Different types of dentifrice
Number of subjects: 120
Study 16945029 — intervention group
Group type: EXPERIMENTAL
Intervention: Order of brushing procedure
Number of subjects: 120
Study 15072892 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (gonadotropin‐releasing hormone agonist or bilateral orchiectomy)
Number of subjects: 79
Study 11424777 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 75 mg i.m.
Number of subjects: 40
Study 11424777 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg i.m.
Number of subjects: 40
Study 9105521 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose immunotherapy (HDI) group (MTD >= 4 micrograms Der p 1)
Number of subjects: 43
Study 9105521 — intervention group
Group type: COMPARATOR
Intervention: Conventional immunotherapy (CI) group (MTD < 4 micrograms Der p 1)
Number of subjects: 43
Study 8394858 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir, 5 mg/kg twice daily for 14 days followed by 5 mg/kg once daily for 14 weeks
Number of subjects: 35
Study 8394858 — intervention group
Group type: COMPARATOR
Intervention: Deferred treatment (control)
Number of subjects: 35
Study 8394858 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir
Number of subjects: 35
Study 2941267 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care antihypertensive therapy
Number of subjects: 0
Study 2941267 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide treated patients
Number of subjects: 0
Study 29983748 — intervention group
Group type: EXPERIMENTAL
Intervention: Metatarsal pad condition
Number of subjects: 36
Study 29983748 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomically-based masking protocol
Number of subjects: 36
Study 29983748 — intervention group
Group type: COMPARATOR
Intervention: Traditional masking protocol
Number of subjects: 36
Study 27684835 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 60
Study 27684835 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 60
Study 24909530 — intervention group
Group type: EXPERIMENTAL
Intervention: Online testable pathogenesis maps
Number of subjects: 65
Study 24909530 — intervention group
Group type: COMPARATOR
Intervention: Existing online resources
Number of subjects: 65
Study 24909530 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogenesis maps (both groups)
Number of subjects: 65
Study 24909530 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogenesis maps
Number of subjects: 65
Study 23039014 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic tablets (2 tablets daily for 1 month)
Number of subjects: 44
Study 23039014 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets (2 tablets daily for 1 month)
Number of subjects: 44
Study 20127873 — intervention group
Group type: EXPERIMENTAL
Intervention: High alexithymia
Number of subjects: 34
Study 20127873 — intervention group
Group type: COMPARATOR
Intervention: Low alexithymia
Number of subjects: 34
Study 18353996 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg b.i.d.
Number of subjects: 19
Study 18353996 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg b.i.d.
Number of subjects: 19
Study 18353996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 15741708 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized-form (PF) letter messages
Number of subjects: 1574
Study 15741708 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized-tailored (PT) letter messages
Number of subjects: 1574
Study 15741708 — intervention group
Group type: COMPARATOR
Intervention: Control (no letter)
Number of subjects: 1574
Study 12218522 — intervention group
Group type: EXPERIMENTAL
Intervention: Gertie Marx needle (127 mm long)
Number of subjects: 73
Study 12218522 — intervention group
Group type: COMPARATOR
Intervention: Sprotte needle (120 mm long)
Number of subjects: 73
Study 12218522 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 73
Study 10064669 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS-fentanyl (transdermal fentanyl system)
Number of subjects: 11
Study 7586783 — intervention group
Group type: EXPERIMENTAL
Intervention: Azapropazone (APZ) 300 mg t.i.d. for three weeks
Number of subjects: 63
Study 7586783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 2405747 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aerosol (25 mg per actuation, qid, for 4 weeks)
Number of subjects: 180
Study 2405747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 2405747 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aerosol
Number of subjects: 180
Study 2405747 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide aerosol and Placebo
Number of subjects: 180
Study 7408227 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar diathermy for haemostasis in tonsillectomy
Number of subjects: 0
Study 31860405 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloablative conditioning (MAC)
Number of subjects: 0
Study 31860405 — intervention group
Group type: COMPARATOR
Intervention: Reduced-intensity conditioning (RIC)
Number of subjects: 0
Study 31305092 — intervention group
Group type: EXPERIMENTAL
Intervention: Dishonest behavior
Number of subjects: 2588
Study 29210815 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice from home care nurses on fiber intake, liquid intake, mobilization, laxative administration, and physician referral
Number of subjects: 59
Study 26373705 — intervention group
Group type: EXPERIMENTAL
Intervention: Laxative therapy (lactulose and enemas)
Number of subjects: 88
Study 26373705 — intervention group
Group type: COMPARATOR
Intervention: Control (absence of defecation tolerated up to 5 days)
Number of subjects: 88